Timber Pharmaceuticals (TMBR) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 24, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	BioPharmX Corp
Entity Central Index Key	1504167
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$1,300,000
Entity Common Stock, Shares Outstanding		11,415,416
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$2,111,000	$3,000
Accounts receivable	2,000
Inventory	138,000
Prepaid expenses and other current assets	269,000	36,000
Total current assets	2,520,000	39,000
Property and equipment, net	235,000	32,000
Intangible assets	150,000	150,000
Other assets	50,000	150,000
Restricted cash	35,000
Total assets	2,990,000	371,000
Current liabilities:
Accounts payable	486,000	229,000
Accrued liabilities	426,000	198,000
Payroll liabilities	199,000	64,000
Deferred rent	51,000	65,000
Deferred revenue	6,000
Related party payables	199,000	125,000
Convertible notes, short-term		90,000
Total current liabilities	1,367,000	771,000
Convertible notes payable		938,000
Other long-term liabilities		32,000
Total liabilities	1,367,000	1,741,000
Commitments and contingencies (Note 11)
Stockholders' deficit:
Common stock, $0.001 par value; 90,000,000 shares authorized; 11,395,311 and 7,025,000 shares issued and outstanding at December 31, 2014 and 2013, respectively	11,000	7,000
Additional paid in capital	4,372,000	306,000
Accumulated deficit	-9,490,000	-1,683,000
Total stockholders' deficit	-5,107,000	-1,370,000
Total liabilities, convertible redeemable preferred stock and stockholder's deficit	2,990,000	371,000
Series A Convertible Redeemable Preferred Stock
Current liabilities:
Series A convertible redeemable preferred stock, $0.001 par value; 10,000,000 shares authorized; 4,207,987 and no shares issued and outstanding at December 31, 2014, and 2013, respectively (liquidation preference of $7.9 million as of December 31, 2014)	$6,730,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	90,000,000	90,000,000
Common stock, issued	11,375,311	7,025,000
Common stock, shares outstanding	11,375,311	7,025,000
Series A Convertible Redeemable Preferred Stock
Par value (in dollars per share)	$0.00	$0.00
Shares authorized	10,000,000	10,000,000
Shares issued	4,207,987	0
Shares outstanding	4,207,987	0
Liquidation preference	$7.90

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$2,519	$671
Sales and marketing	2,299	132
General and administrative	2,953	711
Total operating expenses	7,771	1,514
Loss from operations	-7,771	-1,514
Other Income	40
Interest expense, net	76	74
Net loss	-7,807	-1,588
Accretion on Series A convertible redeemable preferred stock	-163
Deemed dividend on Series A convertible redeemable preferred stock	-159
Net loss available to common stockholders	($8,129)	($1,588)
Basic and diluted net loss per share	($0.80)	($0.22)
Shares used in computing basic and diluted net loss per share	10,217,000	7,119,000

Consolidated_Statements_of_Con

Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders' Deficit (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series A Convertible Redeemable Preferred Stock	Total
Balance Beginning, Amount at Dec. 31, 2012	$7,000	$42,000	($95,000)		($46,000)
Balance Beginning, Shares at Dec. 31, 2012	7,400,000
Repurchase of common stock (in shares)	-375,000
Stock-based compensation		58,000			58,000
Issuance of convertible notes payable with beneficial conversion feature		206,000			206,000
Net and comprehensive loss			-1,588,000		-1,588,000
Balance Ending, Amount at Dec. 31, 2013	7,000	306,000	-1,683,000		-1,370,000
Balance Ending, Shares at Dec. 31, 2013	7,025,000
Balance Beginning, Shares at Dec. 31, 2013				0
Issuance of preferred stock, amount				6,408,000
Issuance of preferred stock, shares				4,207,987
Interest on preferred stock		-159,000		159,000	-159,000
Accretion of stock issuance costs		-163,000		163,000	-163,000
Stock-based compensation		1,193,000			1,193,000
Thompson Designs, Inc. common stock assumed in conjunction with Share Exchange	2,000	-2,000
Thompson Designs, Inc. common stock assumed in conjunction with Share Exchange (in shares)	2,000,000
Issuance of convertible notes payable with beneficial conversion feature		204,000			204,000
Issuance of common stock due to exercise of options and release of awards	1,000	98,000			99,000
Issuance of common stock due to exercise of options and release of awards (in shares)	824,310
Issuance of warrants to non-employees		204,000			204,000
Conversion of convertible notes payable to common stock	1,000	1,846,000			1,847,000
Conversion of convertible notes payable to common stock (in shares)	1,526,001
Issuance of preferred stock and related warrants		845,000			845,000
Net and comprehensive loss			-7,807,000		-7,807,000
Balance Ending, Amount at Dec. 31, 2014	11,000	4,372,000	-9,490,000		-5,107,000
Balance Ending, Amount at Dec. 31, 2014				$6,730,000
Balance Ending, Shares at Dec. 31, 2014	11,375,311
Balance Ending, Shares at Dec. 31, 2014				4,207,987

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($7,807)	($1,588)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,193	58
Depreciation expense	25	5
Warrants issued for services provided	99
Noncash interest expense	76	74
Changes in assets and liabilities:
Accounts receivable	-2
Inventories	-138
Prepaid expenses and other assets	-133	-184
Accounts payable	257	446
Accrued expenses	214
Payroll liabilities	135
Deferred revenue	6
Related party payables	74	109
Net cash used in operating activities	-6,001	-1,080
Cash flows from investing activities:
Change in restricted cash	-35
Purchases of property and equipment	-228	-25
Purchase of intellectual property		-60
Net cash used in investing activities	-263	-85
Cash flows from financing activities:
Proceeds from issuance of common stock	99
Net proceeds from issuance of convertible redeemable preferred stock and common stock warrants	7,253
Proceeds from issuance of convertible notes payable	1,020	1,030
Net cash provided by financing activities	8,372	1,030
Net increase in cash	2,108	-135
Cash at beginning of year	3	138
Cash at end of year	2,111	3
Non-cash investing and financing activities:
Intellectual assets purchase accrued		90
Conversion of convertible notes payable to common stock	1,847
Fair value of beneficial conversion feature issued in connection with convertible notes payable	204	206
Convertible Debt Warrant
Non-cash investing and financing activities:
Issuance of common stock warrants	$105

Formation_and_Business_of_the_

Formation and Business of the Company	12 Months Ended
	Dec. 31, 2014
Formation and Business of the Company
FORMATION AND BUSINESS OF THE COMPANY	1. FORMATION AND BUSINESS OF THE COMPANY
	Description of Business
	BioPharmX Corporation is incorporated under the laws of the state of Delaware and originally incorporated on August 30, 2010 in Nevada under the name Thompson Designs, Inc. We have only one wholly owned subsidiary, BioPharmX, Inc. a Nevada corporation.
	The Company is a specialty pharmaceutical company focused on utilizing our proprietary drug delivery technologies to develop and commercialize novel prescription and over-the-counter, or OTC, products that address large markets in women's health and dermatology. The Company's objective is to develop products that treat health or age-related conditions that (1) are not presently being addressed or treated at all or (2) are currently treated with drug therapies or drug delivery approaches that are suboptimal. The Company's strategy is designed to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for FDA-approved active pharmaceutical ingredients, or APIs, while in appropriate circumstances, reducing the time, cost and risk typically associated with new product development by repurposing drugs with demonstrated safety profiles taking advantage of the regulatory approval pathway under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDC Act available for repurposed/reformulated drugs. The Company believes the 505(b)(2) regulatory pathway may reduce drug development risk and could reduce the time and resources we spend during development.
	Share Exchange
	On January 23, 2014, the Company (then operating as Thompson Designs, Inc.), BioPharmX, Inc. and stockholders of BioPharmX, Inc., who collectively owned 100% of BioPharmX, Inc., entered into and consummated transactions pursuant to a share exchange agreement, such transaction referred to as the Share Exchange, whereby the Company issued to the stockholders of BioPharmX, Inc. an aggregate of 7,025,000 shares of its common stock, in exchange for 100% of the shares of BioPharmX, Inc. held by stockholders. The shares of the Company's common stock received by the stockholders of BioPharmX, Inc. in the Share Exchange constituted approximately 77.8% of our then issued and outstanding common stock, after giving effect to the issuance of shares pursuant to the share exchange agreement. As a result of the Share Exchange, BioPharmX, Inc. became the Company's wholly-owned subsdidiary. For accounting purposes, the Share Exchange was treated as a reverse acquisition with BioPharmX, Inc. as the acquirer and the Company as the acquired party, and as a result the historical financial statements prior to the Share Exchange included in this Annual Report on Form 10-K are the historical financial statements of BioPharmX, Inc. On March 3, 2014, we changed the Company's name to BioPharmX Corporation. On April 25, 2014, the Company reincorporated from Nevada to Delaware.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation and Principles of Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). The accompanying financial statements include the accounts of BioPharmX and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its significant accounting policies or estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates and such differences may be material to the financial statements.
	Reclassification
	Certain prior year amounts have been reclassified to conform to the current year presentation. The amounts for the prior periods have been reclassified to be consistent with the current year presentation and have no impact on previously reported total assets, total stockholders' deficit or net loss.
	Fair Value of Financial Instruments
	Carrying amounts of certain of the Company's financial instruments, including cash, prepaid and other current assets, accounts payable and accrued expenses and related party payables approximate fair value due to their short maturities. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the convertible notes payable approximates fair value.
	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined using the standard cost method which approximates actual cost on a first-in, first-out basis. Market value is determined as the lower of replacement cost or net realizable value. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.
	Shipping and Handling Costs
	Shipping and handling costs are expensed as incurred and are included in cost of revenue.
	Revenue Recognition
	The Company shipped its first product to a retailer in December 2014. The product, the VI2OLET breast health tablet, is a new product in the dietary supplement field. Revenue is recognized provided that persuasive evidence of a sales arrangement exists, the price is fixed or determinable, title and risk of loss has transferred, calculability of the resulting receivable is reasonably assured, there are no customer acceptance requirements and we do not have any significant post-shipment obligations. The Company recognizes revenue on a sell through basis since we do not have the historical information to estimate product returns. As a result, the Company accounts for these product shipments using a deferred revenue recognition model. Under the deferred revenue recognition model, the Company does not recognize revenue upon product shipment. For these product shipments, the Company invoices the reseller, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company recognizes revenue when product is sold by the reseller to the end-user, on a first-in first-out (FIFO) basis.
	Property and Equipment
	Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows:
	Description	Estimated
		Useful Life
	Furniture	5 and 7
	Laboratory and manufacturing equipment	5
	Computer & network equipment	3
	Software	3
	Intangible Assets
	Intangible assets related to in-process research and development (IPR&D) projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development (R&D) efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis as well as between annual tests if we become aware of any events or changes that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.
	As of December 31, 2014 there have been no sales of VI2OLET. As such, the amortization period associated with the intangible asset has not commenced.
	Intangible assets with finite useful lives are amortized over their estimated useful lives. Intangible assets with finite useful lives are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset's carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
	Income Taxes
	The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more likely than not that the benefit will not be realized for the deferred tax assets.
	The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of the date of adoption of accounting for uncertain tax positions there was no accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense recognized during the year.
	Comprehensive Loss
	Comprehensive loss is the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss includes certain changes in equity that are excluded from net loss. For the years ended December 31, 2014 and 2013, the Company's comprehensive loss is equal to the net loss. There were no components of other comprehensive loss for any of the periods presented.
	Research and Development Expenses
	Research and development expenses are expensed as incurred and consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (CROs), materials and supplies and overhead allocations consisting of various and facilities-related costs.
	Stock-Based Compensation
	The Company recognizes stock-based compensation for awards granted to employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value using the Black-Scholes pricing model.
	The Company records stock-based compensation expense for awards granted to non-employees, excluding non-employee directors, based upon the estimated then-current fair value of the equity instrument using the Black-Scholes pricing model. The Company charges the value of the equity instrument to the Consolidated Statements of Operations and Comprehensive Loss over the term of the service agreement and the unvested shares underlying the option are subject to periodic revaluation over the remaining vesting period.
	Advertising Expenses
	The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $68,000 and $7,000 in 2014 and 2013, respectively.
	Net Loss Per Share Attributable to BioPharmX Common Stockholders
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to BioPharmX common stockholders:
		2014			2013
	Numerator:
	Net loss attributable to BioPharmX stockholders (in thousands)	$	(8,129	)	$	(1,588	)
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
	Effect of dilutive securities:
	Stock options and equivalents		—			—
	Convertible preferred stock		—			—
	Weighted-average shares of common stock outstanding used in the calculation of diluted net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
	Basic net loss per share attributable to BioPharmX common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net loss per share attributable to BioPharmX common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and the assumed conversion of convertible notes are determined under the treasury stock method.
	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:
		Years ended December 31,
		2014			2013
	Convertible redeemable preferred stock		4,207,987			—
	Stock options and awards to purchase common stock		2,802,690			2,606,000
	Common stock warrants		2,702,537			—
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, (ASU 2014-09), which converges the FASB and the International Accounting Standards Board standards on revenue recognition. Areas of revenue recognition that will be affected include, but are not limited to, transfer of control, variable consideration, allocation of transfer pricing, licenses, time value of money, contract costs and disclosures. This guidance is effective for the fiscal years and interim reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements and related disclosures.
	On June 10, 2014, the FASB issued ASU 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, (ASU 2014-10), which eliminates the definition of a development stage entity, eliminates the development stage presentation and disclosure requirements under Accounting Standards Codification, or ASC, 915 Development Stage Entities, or ASC 915, and amends provisions of existing variable interest entity guidance under ASC 810 Consolidation . As a result of the changes, entities which meet the former definition of a development stage entity will no longer be required to: (1) present inception-to-date information in the statements of income, cash flows, and stockholder equity; (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged; and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, Risks and Uncertainties, that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities.
	Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December 15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December 15, 2015 for public entities and are effective for annual periods beginning after December 15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities).
	The Company has adopted ASU 2014-10 effective as of its issuance date. Adoption of this standard had no impact on its financial position, results of operations, or cash flows; however, the presentation of the consolidated financial statements and related disclosures in the notes to the consolidated financial statements has been changed to eliminate the disclosures that are no longer required.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (ASU 2014-15). This standard includes guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern within one year after the financial statements are issued. If conditions or events raise substantial doubt, the entity must disclose the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern, management's evaluation of those conditions or events, and management's plans to mitigate the conditions or events. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2014-15 will have on its consolidated financial statements and related disclosures.
The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

Going_Concern_Considerations_a

Going Concern Considerations and Management's Plan	12 Months Ended
	Dec. 31, 2014
Going Concern Considerations and Management's Plan
GOING CONCERN CONSIDERATIONS AND MANAGEMENT'S PLAN	3. GOING CONCERN CONSIDERATIONS AND MANAGEMENT'S PLAN
	The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses and negative cash flows from operations since inception. The Company has not generated revenues and has funded its operating losses through the issuance of convertible notes payable and Series A convertible redeemable preferred stock (Series A). The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the industry.
	The significant risks and uncertainties described herein could have a significant negative impact on the financial viability of BioPharmX and raise substantial doubt about the Company's ability to continue as a going concern. Management is working on the Company's business model to increase working capital by managing its cash flow, securing financing and introducing its first product to market.
	Risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability. Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company's ability to achieve its intended business objectives. These factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not contain any adjustments that might result from the outcome of this uncertainty.
	As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $7.8 million and $1.6 million during the years ended December 31, 2014 and 2013, respectively, and has an accumulated deficit of $9.5 million as of December 31, 2014. As of December 31, 2014, the Company had working capital of $1.2 million. While management of the Company believes that it has a plan to fund on-going operations, there is no assurance that its plan will be successfully implemented. The Company is experiencing the following risks and uncertainties in the business:
	The discovery of key raw materials to formulate novel products depends on the Company's ability to identify, negotiate and secure procurement of such materials. This also depends on the Company's ability to establish comprehensive and long term vendor contracts and relationships.
	The Company's ability to compete and to achieve its product platform strategy depends on its ability to protect its proprietary discoveries and technologies. The Company currently relies on a combination of copyrights, trademarks, trade secret laws and confidentiality agreements to protect its intellectual property rights. The Company also relies upon unpatented know-how and continuing technological innovation.
	The Company's continued operations are dependent upon its ability to identify, recruit and retain adequate management personnel and contractors to perform certain jobs such as research and development, patent generation, regulatory affairs and general administrative functions. The Company requires highly trained professionals of varying levels and experience along with a flexible work force.
	The Company's ability to generate income in the short-run will depend greatly on the rate of adoption and ability to establish a market for the Company's VI2OLET breast health tablet.
	Research and development for novel prescription or OTC based products can be very extensive and lengthy in nature; and the clinical trial process with the Food and Drug Administration can require significant funding and time consuming patient studies. The competitive landscape could change significantly over the time period to complete targeted product development milestones. The current competition for BioPharmX's products could also turn into strategic partners or potential acquirers in the future.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS
	The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value.
	•	Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
	•	Level 2—Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
	•	Level 3—Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity.
	As of December 31, 2014 and 2013, the Company held no assets or liabilities with instrument valuations measured on a recurring basis.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory
INVENTORY	5. INVENTORY
	Inventory at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014		2013
	Work in Process	$	135	$	—
	Finished Goods		2		—
	Channel Inventory		1		—
		$	138	$	—

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment.
PROPERTY AND EQUIPMENT	6. PROPERTY AND EQUIPMENT
	Property and equipment, net at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014			2013
	Furniture	$	18		$	11
	Lab equipment		26			12
	Computers and equipment		78			15
	Software		144			—
			266			38
	Less: accumulated depreciation		(31	)		(6	)
		$	235		$	32
	Depreciation expense for the years ended December 31, 2014 and 2013 was $25,000 and $5,000.

Restricted_Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2014
Restricted Cash
RESTRICTED CASH	7. RESTRICTED CASH
	The Company has restricted cash in the amount of $35,000 held by Bank of America in a money market account to secure the credit line of the Company's credit cards.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities
ACCRUED LIABILITIES	8. ACCRUED LIABILITIES
	Accrued liabilities at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014		2013
	Marketing	$	267	$	—
	Legal		80		89
	Production		57		—
	Intellectual property		—		90
	Other		22		19
	Total accrued liabilities	$	426	$	198

Related_Party_Payables

Related Party Payables	12 Months Ended
	Dec. 31, 2014
Related Party Payables
RELATED PARTY PAYABLES	9. RELATED PARTY PAYABLES
	Since inception, the founding executives of the Company have made advances to cover short-term operating expenses. Additionally, since the beginning of 2014 a portion of their compensation is being deferred and is included in this balance. These advances and deferred compensation are non-interest bearing. As of December 31, 2014 and 2013, related party payables were $199,000 and $125,000, respectively.

LongTerm_Obligations

Long-Term Obligations	12 Months Ended
	Dec. 31, 2014
Long-Term Obligations
LONG-TERM OBLIGATIONS	10. LONG-TERM OBLIGATIONS
	Financing Arrangements
	In September and November 2012, the Company issued convertible notes payable ("Notes") to two individuals, respectively, in exchange for $200,000 in cash. These Notes carry an interest rate of 6% per annum and mature in September and November 2015, respectively, with principal and interest payable at maturity.
	During the year ended December 31, 2013, the Company issued Notes to twelve individuals in exchange for $1.0 million in cash. These notes carry an interest rate of 6% per annum and mature between June 2014 and October 2016, with principal and interest payable at maturity.
	During the first quarter of 2014, the Company issued convertible notes payable to thirteen individuals in exchange for $1.0 million in cash. The Notes carry an interest rate of 6% per annum and mature between January 2015 and March 2017, with principal and interest payable at maturity.
	The Notes automatically convert into common stock upon the Company entering into a qualified preferred stock financing at 80% of the price per share at which such preferred stock is issued in such an offering. Additionally, there is a special conversion that at maturity, unless the Company repays all outstanding principal and interest, the Notes shall be automatically converted into a number of shares of common stock of the Company at 80% of the then fair market value per share.
	As a result of this beneficial conversion feature, the Company recorded $204,000 and $206,000, as a debt discount during the years ended December 31, 2014 and 2013. The debt discount was amortized to interest expense over the term of the Notes using the effective interest rate method. The amortization expense related to the debt discount was $49,000 and $41,000 for the years ended December 31, 2014 and 2013.
	During the year ended December 31, 2014, the Company completed a private placement (the "Private Placement") of shares of its Series A and warrants to purchase common stock ("Warrants"). The Private Placement was consummated in a series of closings that occurred between April 2014 and November 2014. The Company sold to accredited investors and non-U.S. persons 4.2 million shares of Series A at a per share price of $1.85 for total net proceeds of approximately $7.3 million and issued to the investors for no additional consideration the Warrants to purchase in the aggregate 2.0 million shares of the Company's common stock, at an exercise price of $3.70 per share pursuant to a series of subscription agreements. See Note 12.
	As a result, upon the first Series A closing on April 11, 2014, the convertible notes payable balance, net of unamortized discounts, of $1.8 million was converted into 1,526,001 shares of common stock. The balance of the accrued interest was waived. As of December 31, 2014, there were no remaining outstanding convertible notes.

Commitments_and_Contigencies

Commitments and Contigencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies.
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES
	Lease Arrangements
	On August 23, 2013, the Company signed a lease for 10,800 square feet of office and laboratory space in Menlo Park, California. The term of the lease is 39 months from the lease commencement date of September 1, 2013. Future minimum commitments under this lease are as follows (in thousands):
	Years ending December 31,
	2015		$	288
	2016			271
	Total		$	559
	Legal Proceedings
	We are not currently a party to any legal proceedings. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
	Indemnification
	The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company's technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.
	The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
	The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such indemnifications has been recorded to date.
	License Agreement
	In March 2013, the Company entered into an amended and restated collaboration and license agreement with Iogen LLC, which provides the Company the license the rights to label, market, and resell the finished inventory and ongoing manufacturing of the Iogen molecular iodine technology for future product formulation development and commercialization. New formulation patents developed by the Company will be the sole ownership of the Company. The agreement gives the Company a perpetual, fully paid-up, non-exclusive license under the licensed Intellectual Property (IP) rights to make, have made, use, sell, offer for sale and import products.
	Per terms of the license the Company is required to make future payments of:
	•	Pay a fee for acquiring all finished inventory of the Iogen Product.
	•	Pay a fee for the non-exclusive license to the IP.
	•	Pay 30% of net profit associated with direct commercialization of an OTC product or 30% of net royalties received from any sub-licensee.
	•	Pay a royalty of 3% of net sales for the first 12 months of commercialization and 2% of net sales thereafter for other products developed and commercialized under the license, including a prescription version of the iodine tablet.
	•	Pay a fixed royalty fee for the protection and indemnification of licensed IP rights for the prescription product developed, marketed and sold from newly developed formulations as long as the patents are valid and cover the prescription product.
	•	Pay a fixed royalty fee for the protection and indemnification of licensed IP rights for the other products utilizing the molecular iodine technology developed, marketed and sold from newly developed formulations as long as the patents are valid and cover the prescription product.
	The Company capitalized as Intangible Assets, in the year ended December 2013, the amount of $150,000 related to this agreement. No royalties have been paid as of December 31, 2014.

Convertible_Redeemable_Preferr

Convertible Redeemable Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Convertible Redeemable Preferred Stock and Stockholders' Equity
CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	12. CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
	Common Stock
	On March 27, 2013, the Company terminated one of the founders and repurchased 375,000 shares for $18.
	As described in Note 1, on January 23, 2014, the Company issued 7,025,000 shares of its common stock to BioPharmX, Inc. stockholders.
	As described in Note 10, on April 11, 2014, the Company's convertible notes and eligible interest were converted to 1,526,001 shares of common stock upon the first closing of the offer and sale of Series A Preferred Stock.
	During the year ended December 31, 2014, the Company issued 727,643 shares of common stock upon the exercise of stock options.
	In November 2014, the Company issued 290,000 shares of common stock to Korea Investment Partners Expansion Platform Fund of which 96,667 vested immediately and 193,333 will vest upon completion of the $2 million investment outlined in the Series A subscription agreement. The unvested shares are not considered outstanding for financial reporting purposes.
	At December 31, 2014, the Company has 11,375,311 shares of common stock currently issued and outstanding.
	Series A Preferred Stock
	The Company entered into Subscription Agreements for a private placement of shares of our Series A and Warrants with 47 accredited investors during 2014 whereby we sold an aggregate of 4,207,987 shares of Series A at a per share price of $1.85 for gross proceeds of $7.5 million and issued to the investors for no additional consideration the Warrants to purchase in the aggregate 2,042,583 shares of the Company's common stock, with an exercise price of $3.70 per share.
	The Warrants with an allocated fair value of $845,000 were classified as additional paid-in capital. The Company determined the fair value using the Black-Scholes pricing model with the following assumptions: dividend rate of 0%, risk-free rate of 1.6% to 4.0%, contractual term of 5 years and expected volatility of 88.8%. These Warrants were immediately exercisable, and as of December 31, 2014, were all outstanding.
	In connection with the Subscription Agreements, the Company, the majority shareholders of the Company and the Investors entered into Investor Rights Agreements (the Investor Rights Agreements) with the Investors, whereby the Investors were granted certain rights including: (i) right to receive copies of quarterly and annual reports of the Company, (ii) right of inspection of the Company's properties and records, (iii) right of participation in future securities offerings, (iv) tag-along rights in connection with sales of the Company's stock by a major shareholder, and (v) board of directors representation rights for the subscribers who purchased at least 500,000 shares of Series A and hold at least 30% of such shares (the "Qualified Subscribers"). The Company made certain covenants under the agreement including: (i) uplisting to NYSE or NASDAQ within three years from the issuance shares of Series A, and (ii) increase of the board of directors to five members including one member to be appointed by the Qualified Subscribers.
	Significant terms of Series A are as follows:
	•	Holders of the Series A are entitled to interest payment at the rate of 6% of the purchase price per annum. The Company has the option to pay this interest in shares of common stock or in cash. As of December 31, 2014, $159,000 in interest has been accreted to the Series A. Holders of the Series A are entitled to receive dividends on an as converted basis with the holders of the Company's common stock.
	•	The holders of the Series A are entitled to vote together with the holders of the Company's common stock, with each such holder of Series A entitled to the number of votes equal to the number of shares of the Company's common stock into which such Series A would be converted if converted on the record date for the taking of a vote.
	•	Each share of Series A is initially convertible, at any time at the sole option of the holder, into one share of the Company's common stock, subject to future adjustments as provided for in the Series A Certificate. The Series A shall automatically convert into shares of the Company's common stock upon the uplisting of the common stock to NYSE or NASDAQ within three years from the issuance of shares of Series A.
	•	If the Company fails to effect the uplisting within three years from the issuance of shares of Series A, the holders will have the right to require the Company to redeem all or a portion of the then outstanding Series A at a price per share equal to the Series A liquidation preference.
	Warrants
	In addition to the Warrants issued in conjunction with the Subscription Agreements, the Company issued warrants on May 15, 2014, to a service provider for 316,395 shares of common stock at an exercise price of $2.035 per share, which were valued at $99,000 and expensed. The Company also issued to a qualified investor as a part of his convertible loan package for 343,559 shares of common stock at an exercise price of $1.85 per share, which was valued at $105,000. These warrants expire after five years. The Company determined the fair value using the Black-Scholes option pricing model with the following assumptions: dividend rate of 0%, risk-free rate of 1.6%, contractual term of 5 years and expected volatility of 88.8%. These Warrants were immediately exercisable, and as of December 31, 2014, were all outstanding.
	Equity Incentive Plan
	On January 23, 2014, the Company adopted the 2014 Equity Incentive Plan (the "2014 Plan") which permits the Company to grant stock options to directors, officers or employees of the Company or others to purchase shares of common stock of the Company through awards of incentive and nonqualified stock options ("Options"), stock ("Restricted Stock" or "Unrestricted Stock") and stock appreciation rights ("SARs"). Options previously issued under the BioPharmX, Inc. 2011 Equity Incentive Plan were cancelled, and options under the 2014 Plan were issued to replace all cancelled BioPharmX, Inc. options.
	The Company currently has time-based options outstanding. The time-based options generally vest in two to four years and expire ten years from the date of grant. Total number of shares originally reserved and available for grant and issuance pursuant to this Plan was 2,700,000. Shares issued under the Plan will be drawn from authorized and unissued shares or shares now held or subsequently acquired by the Company. On November 7, 2014, the Company increased the stock available to the 2014 Equity Incentive Plan for options grants from 2,700,000 shares to 4,500,000 shares. At December 31, 2014, there were 1,163,000 shares available for grant under the Plan.
	The following table summarizes the Company's stock option activities for the years ended December 31, 2014 and 2013:
			Shares			Weighted			Remaining			Aggregate
						Average			Contractual			Intrinsic
						Exercise			Term			Value
						Price
						Per Share
												(in thousands)
	Outstanding as of January 1, 2013			1,150,000		$	0.06
	Granted			1,456,000			0.4
	Exercised			—			—
	Cancelled			—			—
	Outstanding as of December 31, 2013			2,606,000		$	0.25
	Granted			891,000			1.85
	Exercised			(727,643	)		0.14
	Cancelled			(160,000	)		0.37
	Outstanding as of December 31, 2014			2,609,357		$	0.82			8.52		$	5,686
	Vested and exercisable			972,462		$	0.39			7.71		$	2,542
	Vested and expected to vest			2,490,074		$	0.8			8.49		$	5,478
	The weighted average grant date fair values of the stock options granted during the years ended December 31, 2014 and 2013 were $1.10 and $0.28 per share, respectively.
	The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014 (in thousands, except contractual life and exercise price):
					Options Outstanding									Options Vested and
														Exercisable
			Range of Exercise Price		Number			Weighted			Weighted			Number		Weighted
					Outstanding			Average			Average			Vested and		Average
								Remaining			Exercise			Exercisable		Exercise
								Contractual			Price					Price
								Life (in Years)
			$0.05 - $0.35			1,550,857			7.68		$	0.21			797,462	$	0.17
			$1.00			167,500			6.76		$	1.00			100,000	$	1.00
			$1.85			891,000			9.79		$	1.85			75,000	$	1.85
						2,609,357			8.52		$	0.82			972,462	$	0.39
	The total intrinsic value of employee stock options exercised during the years ended December 31, 2014 and 2013 was $676,000 and zero, respectively.
	As of December 31, 2013, total compensation costs related to unvested, but not yet recognized, stock-based awards was $2,573,000, net of estimated forfeitures. This cost will be amortized on a straight-line basis over a weighted average remaining period of 3.29 years and will be adjusted for subsequent changes in estimated forfeitures.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Stock-Based Compensation
STOCK-BASED COMPENSATION	13. STOCK-BASED COMPENSATION.
	The following table summarizes the stock-based compensation expenses included in our Statement of Operations and Comprehensive Loss for the years ended (in thousands):
		2014			2013
	Research and development	$	228		$	30
	Sales and marketing		147			7
	General and administrative expenses		818			21
	Stock-based compensation expense, net of tax	$	1,193		$	58
	The Company estimates the fair value of time-based stock options, if any, granted using the Black-Scholes pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Time-based and performance-based options, if any, typically have a ten-year life from date of grant and vesting periods of two to four years.
	Valuation Assumptions
	The fair value of stock-based awards to employees is calculated through the use of the Black-Scholes pricing model, even though such model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from the Company's stock option awards. This model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values.
	Expected Term
	The expected term represents the period that the Company's stock-based awards are expected to be outstanding. For awards granted subject only to service vesting requirements, the Company utilizes the simplified method for estimating the expected term of the stock-based award, instead of historical exercise data.
	Expected Volatility
	The Company uses the historical volatility of the price of the common shares of selected public companies in the biotechnology sector.
	Expected Dividend
	The Company has never paid dividends on its common shares and currently does not intend to do so and, accordingly, the dividend yield percentage is zero for all periods.
	Risk-Free Interest Rate
	The Company bases the risk-free interest rate used in the Black-Scholes-Merton valuation method upon the implied yield curve currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term used as the assumption in the model.
	We used the following assumptions to calculate the estimated fair value of the awards for the years ended:
		2014			2013
	Expected volatility		82.2	%	82.10%
	Expected term in years		6.0		5.51 - 6.08
	Risk-free interest rate		1.74	%	0.61% - 1.62%
	Expected dividend yield		—	%	—%

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Employee Benefit Plan
EMPLOYEE BENEFIT PLAN	14. EMPLOYEE BENEFIT PLAN
	The Company sponsors a 401(k) defined contribution plan for its employees. This plan provides for tax-deferred salary deductions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan, as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company may match employee contributions in amounts to be determined at the Company's sole discretion. The Company has made no contributions to the plan for the years ended December 31, 2014 and 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes.
INCOME TAXES	15. INCOME TAXES
	No federal income taxes were provided in the years ended December 31, 2014 and 2013 due to the Company's net losses. State minimum income and franchise taxes are included in general and administrative expenses and were immaterial for the periods presented.
	At December 31, 2014, the Company had available federal net operating loss ("NOL") carry-forwards of approximately $7.6 million which will begin to expire in 2031 and California state NOL carry-forwards of approximately $7.6 million which will begin to expire in 2021. At December 31, 2014 and 2013, the net deferred tax assets of approximately $3.2 million and $594,000, respectively, generated primarily by NOL carry-forwards, have been fully reserved due to the uncertainty surrounding the realization of such benefits. The net valuation allowance increased by approximately $2.6 million and $563,000 during the years ended December 31, 2014 and 2013, respectively.
	Current tax laws impose substantial restrictions on the utilization of net operating loss and credit carry-forwards in the event of an "ownership change," as defined by the Internal Revenue Code. If there should be an ownership change, the Company's ability to utilize its carry-forwards could be limited.
	As of December 31, 2014 and 2013, the Company did not have any material unrecognized tax benefits. The tax years from 2010 to 2014 remain open for examination by the federal and state authorities.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events.
SUBSEQUENT EVENTS	16. SUBSEQUENT EVENTS
	In March 2015, we amended certain warrants to reduce the exercise price of such warrants from $3.70 to $2.50 per share with a corresponding increase in the number of shares of common stock exercisable under the warrants so that the aggregate exercise value of such warrants remained the same. As of March 27, 2015, the holders had exercised such warrants for an aggregate of 397,996 shares of common stock for an aggregate cash exercise price of $994,990.

Recovered_Sheet1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation
	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). The accompanying financial statements include the accounts of BioPharmX and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its significant accounting policies or estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates and such differences may be material to the financial statements.
Reclassification	Reclassification
	Certain prior year amounts have been reclassified to conform to the current year presentation. The amounts for the prior periods have been reclassified to be consistent with the current year presentation and have no impact on previously reported total assets, total stockholders' deficit or net loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Carrying amounts of certain of the Company's financial instruments, including cash, prepaid and other current assets, accounts payable and accrued expenses and related party payables approximate fair value due to their short maturities. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the convertible notes payable approximates fair value.
Inventory	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined using the standard cost method which approximates actual cost on a first-in, first-out basis. Market value is determined as the lower of replacement cost or net realizable value. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.
Shipping and Handling costs	Shipping and Handling Costs
	Shipping and handling costs are expensed as incurred and are included in cost of revenue.
Revenue Recognition	Revenue Recognition
	The Company shipped its first product to a retailer in December 2014. The product, the VI2OLET breast health tablet, is a new product in the dietary supplement field. Revenue is recognized provided that persuasive evidence of a sales arrangement exists, the price is fixed or determinable, title and risk of loss has transferred, calculability of the resulting receivable is reasonably assured, there are no customer acceptance requirements and we do not have any significant post-shipment obligations. The Company recognizes revenue on a sell through basis since we do not have the historical information to estimate product returns. As a result, the Company accounts for these product shipments using a deferred revenue recognition model. Under the deferred revenue recognition model, the Company does not recognize revenue upon product shipment. For these product shipments, the Company invoices the reseller, records deferred revenue at gross invoice sales price, and classifies the cost basis of the product held by the wholesaler as a component of inventory. The Company recognizes revenue when product is sold by the reseller to the end-user, on a first-in first-out (FIFO) basis.
Property and Equipment	Property and Equipment
	Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are as follows:
	Description	Estimated
		Useful Life
	Furniture	5 and 7
	Laboratory and manufacturing equipment	5
	Computer & network equipment	3
	Software	3
Intangible Assets	Intangible Assets
	Intangible assets related to in-process research and development (IPR&D) projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development (R&D) efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis as well as between annual tests if we become aware of any events or changes that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.
	As of December 31, 2014 there have been no sales of VI2OLET. As such, the amortization period associated with the intangible asset has not commenced.
	Intangible assets with finite useful lives are amortized over their estimated useful lives. Intangible assets with finite useful lives are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset's carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
Income Taxes	Income Taxes
	The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more likely than not that the benefit will not be realized for the deferred tax assets.
	The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of the date of adoption of accounting for uncertain tax positions there was no accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense recognized during the year.
Comprehensive Loss	Comprehensive Loss
	Comprehensive loss is the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss includes certain changes in equity that are excluded from net loss. For the years ended December 31, 2014 and 2013, the Company's comprehensive loss is equal to the net loss. There were no components of other comprehensive loss for any of the periods presented.
Research and Development Expenses	Research and Development Expenses
	Research and development expenses are expensed as incurred and consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (CROs), materials and supplies and overhead allocations consisting of various and facilities-related costs.
Stock-Based Compensation	Stock-Based Compensation
	The Company recognizes stock-based compensation for awards granted to employees on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value using the Black-Scholes pricing model.
	The Company records stock-based compensation expense for awards granted to non-employees, excluding non-employee directors, based upon the estimated then-current fair value of the equity instrument using the Black-Scholes pricing model. The Company charges the value of the equity instrument to the Consolidated Statements of Operations and Comprehensive Loss over the term of the service agreement and the unvested shares underlying the option are subject to periodic revaluation over the remaining vesting period.
Advertising Expenses	Advertising Expenses
	The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $68,000 and $7,000 in 2014 and 2013, respectively.
Net Loss Per Share Attributable to BioPharmX Common Stockholders	Net Loss Per Share Attributable to BioPharmX Common Stockholders
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to BioPharmX common stockholders:
		2014			2013
	Numerator:
	Net loss attributable to BioPharmX stockholders (in thousands)	$	(8,129	)	$	(1,588	)
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
	Effect of dilutive securities:
	Stock options and equivalents		—			—
	Convertible preferred stock		—			—
	Weighted-average shares of common stock outstanding used in the calculation of diluted net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
	Basic net loss per share attributable to BioPharmX common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net loss per share attributable to BioPharmX common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and the assumed conversion of convertible notes are determined under the treasury stock method.
	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:
		Years ended December 31,
		2014			2013
	Convertible redeemable preferred stock		4,207,987			—
	Stock options and awards to purchase common stock		2,802,690			2,606,000
	Common stock warrants		2,702,537			—
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, (ASU 2014-09), which converges the FASB and the International Accounting Standards Board standards on revenue recognition. Areas of revenue recognition that will be affected include, but are not limited to, transfer of control, variable consideration, allocation of transfer pricing, licenses, time value of money, contract costs and disclosures. This guidance is effective for the fiscal years and interim reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact that the adoption of ASU 2014-09 will have on its consolidated financial statements and related disclosures.
	On June 10, 2014, the FASB issued ASU 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, (ASU 2014-10), which eliminates the definition of a development stage entity, eliminates the development stage presentation and disclosure requirements under Accounting Standards Codification, or ASC, 915 Development Stage Entities, or ASC 915, and amends provisions of existing variable interest entity guidance under ASC 810 Consolidation . As a result of the changes, entities which meet the former definition of a development stage entity will no longer be required to: (1) present inception-to-date information in the statements of income, cash flows, and stockholder equity; (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged; and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. Furthermore, ASU 2014-10 clarifies disclosures about risks and uncertainties under ASC Topic 275, Risks and Uncertainties, that apply to companies that have not commenced planned principal operations. Finally, variable interest entity rules no longer contain an exception for development stage entities and, as a result, development stage entities will have to be evaluated for consolidation in the same manner as non-development stage entities.
	Under ASU 2014-10, entities are no longer required to apply the presentation and disclosure provisions of ASC 915 during annual periods beginning after December 15, 2014. In addition, the revisions to the consolidation standards are effective for annual periods beginning after December 15, 2015 for public entities and are effective for annual periods beginning after December 15, 2016 for nonpublic entities. Early adoption is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities).
	The Company has adopted ASU 2014-10 effective as of its issuance date. Adoption of this standard had no impact on its financial position, results of operations, or cash flows; however, the presentation of the consolidated financial statements and related disclosures in the notes to the consolidated financial statements has been changed to eliminate the disclosures that are no longer required.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (ASU 2014-15). This standard includes guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern within one year after the financial statements are issued. If conditions or events raise substantial doubt, the entity must disclose the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern, management's evaluation of those conditions or events, and management's plans to mitigate the conditions or events. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2014-15 will have on its consolidated financial statements and related disclosures.
	The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
Property and equipment
	Description	Estimated
		Useful Life
	Furniture	5 and 7
	Laboratory and manufacturing equipment	5
	Computer & network equipment	3
	Software	3
Reconciliation of numerator and denominator
		2014			2013
	Numerator:
	Net loss attributable to BioPharmX stockholders (in thousands)	$	(8,129	)	$	(1,588	)
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
	Effect of dilutive securities:
	Stock options and equivalents		—			—
	Convertible preferred stock		—			—
	Weighted-average shares of common stock outstanding used in the calculation of diluted net loss per share attributable to BioPharmX common stockholders		10,217,000			7,119,000
Schedule of outstanding shares of common stock equivalents excluded from the computation of diluted net loss per share
		Years ended December 31,
		2014			2013
	Convertible redeemable preferred stock		4,207,987			—
	Stock options and awards to purchase common stock		2,802,690			2,606,000
	Common stock warrants		2,702,537			—

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory
Inventory	Inventory at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014		2013
	Work in Process	$	135	$	—
	Finished Goods		2		—
	Channel Inventory		1		—
		$	138	$	—

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment.
Property and Equipment	Property and equipment, net at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014			2013
	Furniture	$	18		$	11
	Lab equipment		26			12
	Computers and equipment		78			15
	Software		144			—
			266			38
	Less: accumulated depreciation		(31	)		(6	)
		$	235		$	32

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities
Accrued Liabilities	Accrued liabilities at December 31, 2014 and 2013 consisted of the following (in thousands):
		2014		2013
	Marketing	$	267	$	—
	Legal		80		89
	Production		57		—
	Intellectual property		—		90
	Other		22		19
	Total accrued liabilities	$	426	$	198

Commitments_and_Contigencies_T

Commitments and Contigencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies.
Future minimum commitments under lease	Future minimum commitments under this lease are as follows (in thousands):
	Years ending December 31,
	2015	$	288
	2016		271
	Total	$	559

Convertible_Redeemable_Preferr1

Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Redeemable Preferred Stock and Stockholders' Equity
Stock option plan activity
		Shares			Weighted			Remaining			Aggregate
					Average			Contractual			Intrinsic
					Exercise			Term			Value
					Price
					Per Share
											(in thousands)
	Outstanding as of January 1, 2013		1,150,000		$	0.06
	Granted		1,456,000			0.4
	Exercised		—			—
	Cancelled		—			—
	Outstanding as of December 31, 2013		2,606,000		$	0.25
	Granted		891,000			1.85
	Exercised		(727,643	)		0.14
	Cancelled		(160,000	)		0.37
	Outstanding as of December 31, 2014		2,609,357		$	0.82			8.52		$	5,686
	Vested and exercisable		972,462		$	0.39			7.71		$	2,542
	Vested and expected to vest		2,490,074		$	0.8			8.49		$	5,478
Schedule of significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2014 (in thousands, except contractual life and exercise price):
				Options Outstanding									Options Vested and
													Exercisable
		Range of Exercise Price		Number			Weighted			Weighted			Number		Weighted
				Outstanding			Average			Average			Vested and		Average
							Remaining			Exercise			Exercisable		Exercise
							Contractual			Price					Price
							Life (in Years)
		$0.05 - $0.35			1,550,857			7.68		$	0.21			797,462	$	0.17
		$1.00			167,500			6.76		$	1.00			100,000	$	1.00
		$1.85			891,000			9.79		$	1.85			75,000	$	1.85
					2,609,357			8.52		$	0.82			972,462	$	0.39

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Stock-Based Compensation
Summary of stock based compensation expense	The following table summarizes the stock-based compensation expenses included in our Statement of Operations and Comprehensive Loss for the years ended (in thousands):
		2014			2013
	Research and development	$	228		$	30
	Sales and marketing		147			7
	General and administrative expenses		818			21
	Stock-based compensation expense, net of tax	$	1,193		$	58
Black scholes option pricing model fair value assumptions
		2014			2013
	Expected volatility		82.2	%	82.10%
	Expected term in years		6.0		5.51 - 6.08
	Risk-free interest rate		1.74	%	0.61% - 1.62%
	Expected dividend yield		—	%	—%

Formation_and_Business_of_the_1

Formation and Business of the Company (Details)	0 Months Ended
	Jan. 23, 2014	Dec. 31, 2014	Jan. 23, 2014
		item
Other Disclosures
Number of wholly owned subsidiaries		1
Thompson Designs, Inc. common stock assumed in conjunction with Share Exchange (in shares)	7,025,000
Ownership interest held by BPX Stockholders	77.80%		77.80%
BPX
Other Disclosures
Ownership interest acquired in exchange	100.00%		100.00%

Recovered_Sheet2

Summary Of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue Recognition
Revenue recognized	$0
Income Tax Uncertainties
Unrecognized tax benefits, income tax penalties and interest accrued	0
Unrecognized tax benefits, interest on income tax expense	0
Marketing and Advertising Expense
Advertising Expense	$68,000	$7,000
Furniture | Minimum
Property, and Equipment
Estimated Useful Life	5 years
Furniture | Maximum
Property, and Equipment
Estimated Useful Life	7 years
Laboratory and Manufacturing Equipment
Property, and Equipment
Estimated Useful Life	5 years
Computers and Network Equipment
Property, and Equipment
Estimated Useful Life	3 years
Software
Property, and Equipment
Estimated Useful Life	3 years

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss attributable to BioPharmX stockholders	($8,129)	($1,588)
Denominator:
Weighted-average shares of common stock outstanding used in the calculation of basic net loss per share attributable to BioPharmX common stockholders	10,217,000	7,119,000
Effect of dilutive securities:
Weighted-average shares of common stock outstanding used in the calculation of diluted net loss per share attributable to BioPharmX common stockholders	10,217,000	7,119,000
Convertible Redeemable Preferred Stock
Effect of dilutive securities:
Anti dilutive securities excluded from computation of diluted net loss per share	4,207,987
Stock options and awards to purchase common stock
Effect of dilutive securities:
Anti dilutive securities excluded from computation of diluted net loss per share	2,802,690	2,606,000
Common Stock Warrants
Effect of dilutive securities:
Anti dilutive securities excluded from computation of diluted net loss per share	2,702,537

Going_Concern_Considerations_a1

Going Concern Considerations and Management's Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Going Concern Considerations and Management's Plan
Net loss	$7,807,000	$1,588,000
Accumulated deficit	-9,490,000	-1,683,000
Working capital	$1,200,000

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory
Work in Process	$135
Finished Goods	2
Channel Inventory	1
Total	$138

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, And Equipment
Total	$266	$38
Less: accumulated depreciation	-31	-6
Property and equipment, net	235	32
Depreciation	25	5
Furniture
Property, And Equipment
Total	18	11
Laboratory and Manufacturing Equipment
Property, And Equipment
Total	26	12
Computers and Network Equipment
Property, And Equipment
Total	78	15
Software
Property, And Equipment
Total	$144

Restricted_Cash_Details

Restricted Cash (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Restricted Cash
Restricted cash	$35

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities
Marketing	$267
Legal	80	89
Production	57
Intellectual property		90
Other	22	19
Total accrued liabilities	$426	$198

Related_Party_Payables_Details

Related Party Payables (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Related party payables	$199,000	$125,000
Founding Executives
Related party payables	$199,000	$125,000

LongTerm_Obligations_Details

Long-Term Obligations (Details) (6% Convertible Notes, USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Nov. 30, 2012	Dec. 31, 2014	Dec. 31, 2013
	item	item		item
6% Convertible Notes
Debt Instrument [Line Items]
Number of purchasers of convertible debt	13	2		12
Issuance of notes in exchange for cash	$1,000,000	$200,000		$1,000,000
Interest rate on convertible notes	6.00%	6.00%		6.00%
Percentage of fair value of common stock used for conversion price at maturity			80
Debt discount recognized			204,000	206,000
Amortization of debt discount			$49,000	$41,000

LongTerm_Obligations_Details_2

Long-Term Obligations (Details 2) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Temporary Equity [Line Items]
Common stock, par value (in dollars per share)	$0.00	$0.00
Series A Convertible Redeemable Preferred Stock
Temporary Equity [Line Items]
Number of shares issued	4,207,987
Share Price	$1.85
Warrant | Series A Warrant
Temporary Equity [Line Items]
Warrants to purchase shares	2,042,583
Warrants exercise price	$3.70
Private Placement | Series A Warrant
Temporary Equity [Line Items]
Warrants to purchase shares	2,000,000
Warrants exercise price	$3.70
Private Placement | Series A Convertible Redeemable Preferred Stock
Temporary Equity [Line Items]
Number of shares issued	4,200,000
Share Price	$1.85
Proceeds from transactions	$7.30

LongTerm_Obligations_Details_3

Long-Term Obligations (Details 3) (6% Convertible Notes, USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 11, 2014	Dec. 31, 2014
6% Convertible Notes
Debt Instrument [Line Items]
Balance, net of unamortized discounts, converted	$1.80
Shares issued for conversion of notes payable	1,526,001
Convertible notes payable		$0

Commitments_and_Contigencies_D

Commitments and Contigencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
	sqft
Future Minimum Commitments [Abstract]
Leased office and laboratory space	10,800
Lease term	39 months
2015	$288
2016	271
Total	$559

Commitments_and_Contigencies_D1

Commitments and Contigencies (Details 2)	12 Months Ended
	Dec. 31, 2014
License Agreement
Legal proceedings description	5.00%
License Agreement | Iogen LLC
License Agreement
Non Royalty license fee equal to a certain percentage of net profit associated with OTC product	30.00%
Non Royalty license fee equal to a certain percentage of net royalties received from any sub-licensee	30.00%
Royalty fee percentage based on net sales over a specific time period of commercialization	3.00%
Royalty fee percentage based on net sales after a specific period of time	2.00%
Time period for determining initial royalty fee as a percent of net sales	12 months

Commitments_and_Contigencies_D2

Commitments and Contigencies (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Indefinite-lived Intangible Assets [Line Items]
Royalties paid	$0
Intellectual Property
Indefinite-lived Intangible Assets [Line Items]
Fees to Iogen capitalized		$150,000

Convertible_Redeemable_Preferr2

Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) (USD $)	0 Months Ended		12 Months Ended	0 Months Ended
	Jan. 23, 2014	Mar. 27, 2013	Dec. 31, 2014	Apr. 11, 2014	Dec. 31, 2013	Nov. 30, 2014
Convertible Redeemable Preferred Stock and Stockholders' Equity
Number of founders terminated		1
Shares repurchased		375,000
Shares repurchased amount		$18,000
Statement [Line Items]
Stock issued to BioPharmX shareholders	7,025,000
Stock issued upon the exercise of stock options			727,643
Stock issued			11,375,311		7,025,000
Stock outstanding			11,375,311		7,025,000
Common Stock
Statement [Line Items]
Stock issued to BioPharmX shareholders	7,025,000		2,000,000
Stock issued on conversion of convertible notes				1,526,001
Stock issued upon the exercise of stock options			727,643
Stock issued			11,375,311
Stock outstanding			11,375,311
Korea Investment Partners
Statement [Line Items]
Stock issued						290,000
Stock vested						96,667
Stock expected to vest						193,333
Investment limit for vesting remaining common stock						$2,000,000

Convertible_Redeemable_Preferr3

Convertible Redeemable Preferred Stock and Stockholders' Equity (Details 2) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	15-May-14	Dec. 31, 2013
Temporary Equity [Line Items]
Common stock, par value (in dollars per share)	$0.00		$0.00
Adjustment to paid-in capital, warrant fair value	$204,000
Series A Warrant | Warrant
Temporary Equity [Line Items]
Number of shares of common stock subject to warrant	2,042,583
Warrants exercise price	$3.70
Adjustment to paid-in capital, warrant fair value	845,000
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Dividend rate	0.00%
Contractual term	5 years
Expected volatility	88.80%
Series A Warrant | Warrant | Minimum
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Risk-free rate	1.60%
Series A Warrant | Warrant | Maximum
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Risk-free rate	4.00%
Service Provider Warrant | Warrant
Temporary Equity [Line Items]
Number of shares of common stock subject to warrant		316,395
Warrants exercise price		$2.04
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Warrant expense		99,000
Convertible Debt Warrant | Warrant
Temporary Equity [Line Items]
Number of shares of common stock subject to warrant	343,559
Warrants exercise price	$1.85
Adjustment to paid-in capital, warrant fair value	105,000
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Dividend rate	0.00%
Risk-free rate	1.60%
Contractual term	5 years
Expected volatility	88.80%
Series A Convertible Redeemable Preferred Stock
Temporary Equity [Line Items]
Preferred stock, par value	$0.00		$0.00
Number of shares sold	4,207,987
Price per share	$1.85
Gross proceeds from issuance	7,500,000
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Number of shares required to obtain Board representation	500,000
Period of time for listing	3 years
Issuance covenant, Required number of Board of Director members	5
Issuance covenant, Number of Board Of Director members appointed by qualified subscribers	1
Interest rate	6.00%
Interest accreted	$159,000
Number of common shares into which share is convertible	1
Series A Convertible Redeemable Preferred Stock | Minimum
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]
Percentage of shares outstanding required to obtain Board representation	30.00%
Series A Convertible Redeemable Preferred Stock | Subscription Agreement [Member]
Temporary Equity [Line Items]
Number of shares sold	4,207,987
Series A Convertible Redeemable Preferred Stock | Series A Warrant
Temporary Equity [Line Items]
Number of purchasers of stock	47

Convertible_Redeemable_Preferr4

Convertible Redeemable Preferred Stock and Stockholders' Equity (Details 3)	12 Months Ended
	Dec. 31, 2014	Nov. 07, 2014	Jan. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant	1,163,000
Number of shares reserved and available for grant		4,500,000	2,700,000
2014 Equity Incentive Plan | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
2014 Equity Incentive Plan | Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
2014 Equity Incentive Plan | Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Convertible_Redeemable_Preferr5

Convertible Redeemable Preferred Stock and Stockholders' Equity (Details 4) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding, Beginning	2,606,000	1,150,000
Granted	891,000	1,456,000
Exercised	-727,643
Cancelled	-160,000
Outstanding, Ending	2,609,357	2,606,000
Vested and exercisable	972,462
Vested and expected to vest	2,490,074
Weighted Average Exercise Price
Outstanding, Beginning	$0.25	$0.06
Granted	$1.85	$0.40
Cancelled	$0.14
Forfeited	$0.37
Outstanding, Ending	$0.82	$0.25
Vested and exercisable	$0.39
Vested and expected to vest	$0.80
Weighted-average grant date fair value (in dollars per share)	$1.10	$0.28
Remaining contractual term
Outstanding	8 years 6 months 7 days
Vested and exercisable	7 years 8 months 16 days
Vested and expected to vest	8 years 5 months 27 days
Aggregate intrinsic value of stock options outstanding and exercisable	$5,478
Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Abstract]
Outstanding	5,686
Vested and exercisable	2,542
Vested and expected to vest	$5,478

Convertible_Redeemable_Preferr6

Convertible Redeemable Preferred Stock and Stockholders' Equity (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Options Outstanding
Number Outstanding (in shares)	2,609,357
Weighted Average Remaining Contract Life	8 years 6 months 7 days
Weighted Average Exercise Prices (in dollars per share)	$0.82
Options Exercisable
Number Exercisable (in shares)	972,462
Weighted Average Exercise Price (in dollars per share)	$0.39
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Total intrinsic value of options exercised	$676,000	$0
Total compensation costs not yet recognized		$2,573,000
Average remaining amortization period for recognition of expense		3 years 3 months 15 days
$0.05 - $0.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise prices, low end of range (in dollars per share)	$0.05
Exercise prices, high end of range (in dollars per share)	$0.35
Options Outstanding
Number Outstanding (in shares)	1,550,857
Weighted Average Remaining Contract Life	7 years 8 months 5 days
Weighted Average Exercise Prices (in dollars per share)	$0.21
Options Exercisable
Number Exercisable (in shares)	797,462
Weighted Average Exercise Price (in dollars per share)	$0.17
$1.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise prices, high end of range (in dollars per share)	$1
Options Outstanding
Number Outstanding (in shares)	167,500
Weighted Average Remaining Contract Life	6 years 9 months 4 days
Weighted Average Exercise Prices (in dollars per share)	$1
Options Exercisable
Number Exercisable (in shares)	100,000
Weighted Average Exercise Price (in dollars per share)	$1
$1.85
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise prices, high end of range (in dollars per share)	$1.85
Options Outstanding
Number Outstanding (in shares)	891,000
Weighted Average Remaining Contract Life	9 years 9 months 15 days
Weighted Average Exercise Prices (in dollars per share)	$1.85
Options Exercisable
Number Exercisable (in shares)	75,000
Weighted Average Exercise Price (in dollars per share)	$1.85

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation
Stock-based compensation expense, net of tax	$1,193	$58
Expiration period	10 years
Minimum
Share-based Compensation
Vesting period	2 years
Maximum
Share-based Compensation
Vesting period	4 years
Research and Development
Share-based Compensation
Stock-based compensation expense, net of tax	228	30
Sales and Marketing
Share-based Compensation
Stock-based compensation expense, net of tax	147	7
General and Administrative Expenses
Share-based Compensation
Stock-based compensation expense, net of tax	$818	$21

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	82.12%	82.10%
Expected term in years	6 years
Risk-free interest rate	1.74%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years		5 years 6 months 4 days
Risk-free interest rate		0.61%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years		6 years 1 month 6 days
Risk-free interest rate		1.62%

Employee_Benefit_Plan_Details

Employee Benefit Plan ( Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Benefit Plan
Employee maximum contribution percentage	100.00%
Employer discretionary contribution amount	$0	$0

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal income taxes	$0	$0
Net deferred tax assets	3,200,000	594,000
Increase in valuation	2,600,000	563,000
Federal
Operating loss carryforwards	7,600,000
Expiration year	31-Dec-31
State | California
Operating loss carryforwards	$7,600,000
Expiration year	31-Dec-21

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent event, Series A Warrant, USD $)	1 Months Ended
	Mar. 27, 2015
Previously Reported
Subsequent Event [Line Items]
Warrants exercise price	$3.70
Actual
Subsequent Event [Line Items]
Warrants exercise price	$2.50
Common Stock
Subsequent Event [Line Items]
Number of warrants exercised (in shares)	397,996
Proceeds from Warrant Exercises	$994,990